We are live on ! Find out more
ORKA icon

Oruka Therapeutics
ORKA

12 hedge funds and large institutions have $1.2M invested in Oruka Therapeutics in 2019 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

244% more capital inflows, than outflows

Capital inflows: $307K | Capital outflows: $89K

1.61% more ownership

Funds ownership: 11.67% → 13.28% (+1.6%)

0% more funds holding

Funds holding: 12 → 12 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
12
Holders Change
–
Holders Change %
0%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$227K
2
JP Morgan Chase
JP Morgan Chase
New York
+$51.7K
3
UBS Group
UBS Group
Switzerland
+$16.3K
4
Deutsche Bank
Deutsche Bank
Germany
+$11.8K
5
Financial Management Professionals
Financial Management Professionals
Texas
+$64

Top Sellers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
-$75K
2
Quantamental Technologies
Quantamental Technologies
New York
-$13K
3
Victory Capital Management
Victory Capital Management
Texas
-$1K

ORKA Hedge Fund Activity: Q4 2019 in Review

12 of the 5,094 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q4 2019, worth a combined $1.2M — up 32% from $910K a quarter earlier.

Fund positioning in ORKA was balanced in Q4 2019: 4 funds opened new positions, 4 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $227K. The largest seller was A.R.T. Advisors, exiting entirely with an estimated $75K sold.

  • 12 institutional investors held Oruka Therapeutics (ORKA) as of Q4 2019, unchanged from Q3 2019.
  • Funds reported $1.2M of Oruka Therapeutics stock for Q4 2019, up 32% quarter-over-quarter.
  • 4 funds opened new Oruka Therapeutics positions in Q4 2019 and 4 closed out, a net change of 0 holders.
  • The largest Oruka Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $227K added.
  • The largest Oruka Therapeutics seller in Q4 2019 was A.R.T. Advisors, an estimated $75K sold.

Based on aggregated 13F filings for Q4 2019.